Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2025 08:30 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Gildeuretinol Data Will Be Presented During the 13th International FLORetina ICOOR Congress December 4–7 in Florence, Italy

Alkeus Pharmaceuticals announces gildeuretinol data will be presented during the 13th International FLORetina ICOOR Congress Dec. 4–7 in Florence, Italy
December 02, 2025 08:00 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Appoints Renowned Retina Specialist and Biotech Executive Carlos Quezada-Ruiz, M.D., F.A.S.R.S., as Chief Medical Officer

Alkeus Pharmaceuticals appoints renowned retina specialist and biotech executive Carlos Quezada-Ruiz, M.D., F.A.S.R.S., as Chief Medical Officer
November 06, 2025 07:58 ET | Source: UroGen Pharma Ltd.

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
May 07, 2025 08:59 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Presents Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025

Alkeus Pharmaceuticals presents gildeuretinol data during the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025
February 25, 2025 08:30 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Establishment of Scientific Advisory Board

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today...
January 09, 2025 08:30 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients

Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A total of five patients have completed the 24-month...
January 07, 2025 10:52 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14.
October 23, 2024 09:00 ET | Source: Alkeus Pharmaceuticals

Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function Improvement

Alkeus Pharmaceuticals, Inc., today announced that results from its study of gildeuretinol in geographic atrophy were presented at AAO 2024.
May 14, 2024 16:05 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE™-1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in...
November 21, 2023 16:30 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...